TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06540198: VENTURE-ORAL: Phase 2b Multicenter Study of Oral VK2735 Dual GLP-1/GIP Receptor Agonist in Obesity and MASH

Sponsor: Viking Therapeutics, Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 280 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$10,624,000

Rescue Site Savings

+$7,005,200

Unlock Full NCT06540198 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06540198 Rescue Dossier →